UCB is a global biopharmaceutical company focused on severe diseases in two therapeutic areas, namely central nervous system disorders and immunology. In the area of central nervous system disorders, Co. is focused on advanced Parkinson's disease, epilepsy, restless legs syndrome and epilepsy. In the area of immunology disorders, Co. is focused on rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, systemic lupus erythematosus, juvenile idiopathic arthritis, post-menopausal osteoporosis, systemic lupus erythematosus and immunological diseases.
  • TickerUCB
  • ISINBE0003739530
  • ExchangeEuronext Brussels
  • SectorPharmaceuticals & Biotechnology
  • CountryBelgium

Analysts

Team Pharma

ODDO : Dans un contexte volatil, nous privilégions AstraZeneca et Novartis

Depuis notre étude du 6 mai dernier « favoriser l’innovation et le recentrage Pharma », le Stoxx 600 Healthcare a progressé de 8.7% vs -0.4% pour le Stoxx 600. Cette performance est notamment expliquée par des publications du S1 de bonne facture. Cependant tributaire des annonces de reformes potentielles de la santé américaine, nous considérons toujours que le secteur devrait rester volatil dans ces prochains mois. Nous maintenons dans ce contexte notre préférence pour AstraZenec...

Team Pharma

ODDO : In a volatile context, we favour AstraZeneca and Novartis

Since the publication of our “Favour innovation and refocusing on pharma” report on the 6 May 2019, the Stoxx 600 Healthcare index has turned in a performance of +8.7% vs -0.4% for the Stoxx 600. This performance is notably attributable to a good set of H1 2019 results publications. However, as the pharma sector is dependent on announcements concerning the potential reforms of the US healthcare system, we think it is likely to remain volatile in the coming months. Against this ba...

Jean-Jacques Le Fur

UCB: H1 results without any surprise | NEUTRAL | EUR69(-5%)

UCB - NEUTRAL | EUR69(-5%) H1 results without any surprise H1 2019 results globally in line – 2019 guidance unchanged Cimzia positively impacted by inventory movements Two years with margin pressure in 2019 and 2020 at least.

Ahmed Ben Salem ...
  • Alain William
  • Alexandre Iatrides
  • Alfred Glaser
  • Baptiste Lebacq
  • Benoit Valleaux
  • Charles Lepetitpas
  • Christophe-Raphaël Ganet
  • Delphine Brault
  • Emira Sagaama
  • Emmanuel Matot
  • Florent Laroche-Joubert
  • François Maury
  • Georges Dieng
  • Jerôme Bodin
  • Johanna Jourdain
  • Laurence Hofmann
  • Louis Boujard
  • Manuel Martin
  • Martial Descoutures
  • Matthias Desmarais
  • Michael Foundoukidis
  • Nicolas David
  • Philippe Ourpatian
  • Pierre Tegner
  • Pierre Corby
  • Roland Pfaender
  • Stephane Houri

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 25/07/2019

...

Martial Descoutures ...
  • Pierre Corby

UCB : Guidance 2019 confirmée

>Cimzia et Vimpat toujours au rendez-vous - La société publie ce matin ses résultats semestriels qui se révèlent 3% au-dessus des attentes au niveau de la marge mais inférieurs sur son BPA. Les ventes restent toujours principalement conduites par Cimzia et Vimpat. En hausse de 10% à tcc au S1, Cimzia continue sa montée en puissance atteignant 782 M€ vs 736 M€ att. UCB bénéficie notamment d’un effet changes positif mais aussi d’une croissance solide sur les trois ...

Team Pharma

ODDO : Dans un contexte volatil, nous privilégions AstraZeneca et Novartis

Depuis notre étude du 6 mai dernier « favoriser l’innovation et le recentrage Pharma », le Stoxx 600 Healthcare a progressé de 8.7% vs -0.4% pour le Stoxx 600. Cette performance est notamment expliquée par des publications du S1 de bonne facture. Cependant tributaire des annonces de reformes potentielles de la santé américaine, nous considérons toujours que le secteur devrait rester volatil dans ces prochains mois. Nous maintenons dans ce contexte notre préférence pour AstraZenec...

Team Pharma

ODDO : In a volatile context, we favour AstraZeneca and Novartis

Since the publication of our “Favour innovation and refocusing on pharma” report on the 6 May 2019, the Stoxx 600 Healthcare index has turned in a performance of +8.7% vs -0.4% for the Stoxx 600. This performance is notably attributable to a good set of H1 2019 results publications. However, as the pharma sector is dependent on announcements concerning the potential reforms of the US healthcare system, we think it is likely to remain volatile in the coming months. Against this ba...

Jean-Jacques Le Fur

UCB: H1 results without any surprise | NEUTRAL | EUR69(-5%)

UCB - NEUTRAL | EUR69(-5%) H1 results without any surprise H1 2019 results globally in line – 2019 guidance unchanged Cimzia positively impacted by inventory movements Two years with margin pressure in 2019 and 2020 at least.

Martial Descoutures ...
  • Pierre Corby

UCB : Guidance 2019 confirmée

>Cimzia et Vimpat toujours au rendez-vous - La société publie ce matin ses résultats semestriels qui se révèlent 3% au-dessus des attentes au niveau de la marge mais inférieurs sur son BPA. Les ventes restent toujours principalement conduites par Cimzia et Vimpat. En hausse de 10% à tcc au S1, Cimzia continue sa montée en puissance atteignant 782 M€ vs 736 M€ att. UCB bénéficie notamment d’un effet changes positif mais aussi d’une croissance solide sur les trois ...

Nurhayati Wan

UCB SA

1 director sold

A director at Ucb SA sold 5,000 shares at 75.000EUR and the significance rating of the trade was 80/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board members ...

Ahmed Ben Salem ...
  • Alain William
  • Alexandre Iatrides
  • Alfred Glaser
  • Baptiste Lebacq
  • Benoit Valleaux
  • Charles Lepetitpas
  • Christophe-Raphaël Ganet
  • Delphine Brault
  • Emira Sagaama
  • Emmanuel Matot
  • Florent Laroche-Joubert
  • François Maury
  • Georges Dieng
  • Jerôme Bodin
  • Johanna Jourdain
  • Laurence Hofmann
  • Louis Boujard
  • Manuel Martin
  • Martial Descoutures
  • Matthias Desmarais
  • Michael Foundoukidis
  • Nicolas David
  • Philippe Ourpatian
  • Pierre Tegner
  • Pierre Corby
  • Roland Pfaender
  • Stephane Houri

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 25/07/2019

...

Christophe Chaput ...
  • Emira Sagaama
  • Jerôme Bodin
  • Laurence Hofmann
  • Louis Boujard
  • Martial Descoutures
  • Matthias Desmarais
  • Philippe Ourpatian
  • Pierre Corby
  • Sven Edelfelt
  • Virginie Rousseau

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 02/28/2019

...

Christophe Chaput ...
  • Emira Sagaama
  • Jerôme Bodin
  • Laurence Hofmann
  • Louis Boujard
  • Martial Descoutures
  • Matthias Desmarais
  • Philippe Ourpatian
  • Pierre Corby
  • Sven Edelfelt
  • Virginie Rousseau

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 28/02/2019

...

Christophe Chaput ...
  • Johanna Jourdain
  • Laurence Hofmann
  • Martial Descoutures
  • Matthias Desmarais
  • Pierre Corby

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 01/09/2019

...

Christophe Chaput ...
  • Johanna Jourdain
  • Laurence Hofmann
  • Martial Descoutures
  • Matthias Desmarais
  • Pierre Corby

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 09/01/2019

...

Nurhayati Wan

UCB SA

Nurhayati Wan

UCB SA

Nurhayati Wan

UCB SA

UCB SA increases its risk exposure and slightly lowers to Neutral

UCB SA (BE), a company active in the Pharmaceuticals industry, now shows a lower overall rating. The independent financial analyst theScreener confirms the fundamental rating of 3 out of 4 stars. However, the market behaviour deterioration triggered a risk requalification, which can be thus described as moderately risky. theScreener believes that increased risk justifies the general evaluation downgrade to Neutral. As of the analysis date July 12, 2019, the closing price was EUR 70.92 and its expected value was estimated at EUR 71.56.

Nurhayati Wan

UCB SA

ING
Hendrik Wiersma ...
  • Job Veenendaal
  • Nadège Tillier
  • Suvi Platerink Kosonen

Benelux Credit Digest/Issuer Profiles

Once again, it is with great pleasure that we present the eleventh edition of our Benelux Credit Digest, our annual overview of the key fundamentals and credit metric developments of the most important corporate and financial credits in Belgium, the Netherlands and Luxembourg.

Rahul Shah CFA ...
  • S.M Galibur Rahman

Bangladesh (IDLC): Banks – Asset quality issues shroud the promising story; we prefer BRAC Bank

We are cautious on the sector. On the back of the recent increase in non-performing loans outstanding, the sector’s systematic risk remains high. However, lower valuation (sector median 0.8x PB) suggests that this systematic risk is mostly priced in. Fundamentally, we expect moderate top-line growth and improved profitability for our coverage names. We use a dividend discount model to derive our target prices.

Expert Corporate Governance Service (ECGS)

UCB _ AGM and EGM 25 April 2019

In general, UCB is in compliance with the Belgian regulations relating to the organization and procedures of the Annual General Meeting. ITEMS 1 to 9 concern the Annual General Meeting. ITEMS E.1, E.2 and E.3 concern the Extraordinary Meeting. In the Ordinary General Meeting, in ITEM 5, the board of directors seeks approval of the Company's remuneration report. Since ECGS does not approve of long term incentive plans that do not operate one or more challenging performance conditions, we recommend to OPPOSE. Three re-elections are proposed: Ms. Evelyn du Monceau (ITEM 8.1), Mr. Cyril Jansse...

UCB– Proxinvest Corporate Governance Rating ® : C

Proxinvest Corporate Governance Rating ® helps investors integrate governance into their investment decision and identify governance risks and opportunities within their portfolio. Proxinvest Corporate Governance Rating ® Service rates European issuers through the analysis of four main themes : Ownership & Shareholder rights, Board & Committees, Audit & Process, Remuneration. Each theme is rated taking into account several comprehensive sub-categories. Our unique two-step process to achieve each rating includes a first step quantitative valuation and a second step qualitative filter...

Expert Corporate Governance Service (ECGS)

Etude de l'AG du 27/04/2017

In general, UCB is in compliance with the Belgian regulations relating to the organization and procedures of the Annual General Meeting.Under ITEM 5, the Board of Directors seeks approval for the Company's remuneration report. Since we do not approve of LT incentive plans that do not operate one or more challenging performance conditions, we recommend opposition.Under ITEM 8.2a, the Nomination Committee proposes to re-elect Mr. Albrecht de Graeve. As we have concerns over his aggregate time commitments, we recommend opposition.Finally, under ITEM 9.1, the Board of Directors seeks authority to ...

Jérôme VINERIER

Short term view - UCB : The trend is bullish.

The trend is bullish. Prices are still making progress but the trend is slowing down. The next resistance is at €76.80. The break of €69.86 would endanger the trend.

Jérôme VINERIER

Analyse court terme - UCB : La tendance est haussière.

La tendance est haussière. Les cours progressent encore, mais la tendance s'affaiblit. La prochaine résistance est à 76,80 €. La rupture de 69,86 € mettrait la tendance en danger.

Jérôme VINERIER

Analyse court terme - UCB : La tendance est incertaine.

La tendance est incertaine. Les cours baissent, mais la tendance manque de puissance pour le moment. Le prochain support est à 69,86 €.

Jérôme VINERIER

Short term view - UCB : The trend is uncertain.

The trend is uncertain. Prices are falling, but the trend is lacking power for the time being. The next support is at €69.86.

Valérie GASTALDY

Medium term view - UCB : The correction is gaining traction.

The background trend is clearly bullish. The correction is gaining traction. It is too early to qualify this action as a bearish reversal. The trend would be invalidated below the support at €52.76.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch